Literature DB >> 7389205

Immunological studies in angioimmunoblastic lymphadenopathy.

A Skibin, T Yeremiyahu, A Keynan, M R Quastel.   

Abstract

Immunological studies were carried out on two female patients with angioimmunoblastic lymphadenopathy (AIL). Both presented with fever, lymphadenopathy, hepatosplenomegaly, rash and apparent ampicillin hypersensitivity. During the active phase of the disease, cellular immunity was depressed and T cell blastogenesis induced by lectins was abnormal. In the first patient, a non-dialysable plasma factor was found that inhibited normal lymphocyte blastogenesis, the removal of which enhanced the activation of AIL lymphocytes. This inhibitory plasma factor was also observed in the second patient during relapse of the disease. The latter patient responded well to steroid and levamisole therapy, showing clinical remission and a return of in vivo and in vitro parameters of cellular immunity. Defective B cell regulation due to impaired suppressor function, followed by immunoglobulin overproduction, is suggested to occur in AIL.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7389205      PMCID: PMC1538044     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease.

Authors:  R J Lukes; B H Tindle
Journal:  N Engl J Med       Date:  1975-01-02       Impact factor: 91.245

2.  Human lymphocyte-sheep erythrocyte rosette formation: some characteristics of the interaction.

Authors:  Z Bentwich; S D Douglas; F P Siegal; H G Kunkel
Journal:  Clin Immunol Immunopathol       Date:  1973-07

3.  Angio-immunoblastic lymphadenopathy with dysproteinaemia.

Authors:  G Frizzera; E M Moran; H Rappaport
Journal:  Lancet       Date:  1974-06-01       Impact factor: 79.321

4.  "Spontaneous" B cell activation due to loss of normal mouse serum suppressor.

Authors:  W W Bullock; E Möller
Journal:  Eur J Immunol       Date:  1972-12       Impact factor: 5.532

5.  [Chronic pluripotential immune proliferative syndrome].

Authors:  M Westerhausen; W Oehlert
Journal:  Dtsch Med Wochenschr       Date:  1972-09-22       Impact factor: 0.628

6.  Depression of lymphocyte reactivity to phytohemagglutinin by serum from patients with liver disease.

Authors:  W M Newberry; J W Shorey; J P Sanford; B Combes
Journal:  Cell Immunol       Date:  1973-01       Impact factor: 4.868

7.  T-cell control of B-cell responsiveness.

Authors:  J F Miller
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

8.  Letter: Immunoblactic lymphadenopathy associated with phenytoin (diphenylhydantoin).

Authors:  M J Lapes; R J Vivacqua; K Antoniades
Journal:  Lancet       Date:  1976-01-24       Impact factor: 79.321

9.  Immunoblastic lymphadenopathy with mixed cryoglobulinemia. A detailed case study.

Authors:  D R Schultz; A A Yunis
Journal:  N Engl J Med       Date:  1975-01-02       Impact factor: 91.245

10.  The effect of in vivo hydrocortisone on subpopulations of human lymphocytes.

Authors:  A S Fauci; D C Dale
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

View more
  3 in total

1.  Evidence for monoclonal T lymphocyte proliferation in angioimmunoblastic lymphadenopathy.

Authors:  N T O'Connor; J A Crick; J S Wainscoat; K C Gatter; H Stein; B Falini; D Y Mason
Journal:  J Clin Pathol       Date:  1986-11       Impact factor: 3.411

2.  Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy.

Authors:  A C Feller; H Griesser; C V Schilling; H H Wacker; F Dallenbach; H Bartels; R Kuse; T W Mak; K Lennert
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

3.  Histological, immunohistological and autopsy findings in lymphogranulomatosis X (including angio-immunoblastic lymphadenopathy).

Authors:  H Knecht; E W Schwarze; K Lennert
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.